Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1183)	3/30/1999 10:44:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 1826

Rick, Well, "discussed at length" is not quite accurate - more like "the abstracts are coming, the abstracts are coming, THE ABSTRACTS ARE COMING." Interesting snippet tucked away in the 10-K: NCI is also screening several new analogs from the acylfulvene family for potential antitumor activity and improved safety profiles. Currently, 10 analogs with activity in the primary in vitro screen have been through additional in vivo testing by NCI. NCI has noted favorable results for all 10 analogs in a hollow fiber in vivo assay. Peter